Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp151 | Neuroendocrinology & Growth Hormones | ECE2017

Growth hormone-releasing hormone (GHRH) antagonists, MIA-602 and MIA-690, inhibit survival and proliferation of human pleural mesothelioma cells

Villanova Tania , Gesmundo Iacopo , Taliano Marina , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due to asbestos exposure. Different growth factors are involved in the pathogenesis of MPM and in resistance to therapy; moreover, chemotherapy with cisplatin and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), apart from stimulating GH secretion in the pituitary, exerts many...

ea0070aep586 | Pituitary and Neuroendocrinology | ECE2020

Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity

Banfi Dana , Gesmundo Iacopo , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Neurogenesis, a process by which new neurons are generated from precursors, still persists in discrete regions of the adult hippocampus. Impairment in neurogenesis is an important feature in the pathogenesis of neurodegenerative diseases, such asAlzheimer’s disease (AD). The hippocampus is critical for learning and memory and is a main target of AD, which causes massive neuronal death, reduction in neurogenesis and impairment in cognitive functions. Therefore, preventing...

ea0073oc13.4 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity

Banfi Dana , Gesmundo Iacopo , Guglielmotto Michela , Tamagno Elena , Ghigo Ezio , Schally Andrew V. , Granata Riccarda

Neurogenesis, a process by which new neurons are generated from precursors, still persists in discrete regions of the adult hippocampus. The hippocampus is critical for learning and memory and is a main target of AD, which causes massive neuronal death, reduction in neurogenesis and impairment in cognitive functions. Therefore, preventing neuronal loss or increasing the production of new neurons may represent a potential therapeutic strategy to reduce AD-induced cognitive decl...

ea0081oc6.5 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Antagonist of growth hormone-releasing hormone (GHRH) potentiates the antitumor effect of chemotherapy in human malignant pleural mesothelioma

Gesmundo Iacopo , Vitale Nicoletta , Orlando Giulia , Bertoldo Alessia , Papotti Mauro , Deaglio Silvia , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Human malignant pleural mesothelioma (MPM) is a rare but aggressive neoplasm, arising from pleural mesothelial cells, generally due exposure to asbestos. Of note, different growth factors and their receptors are involved in the pathogenesis of MPM and resistance to therapy. Chemotherapy with cisplatin (cis) and antifolates, like pemetrexed (PEM), is the first-line treatment for inoperable MPM. Growth hormone-releasing hormone (GHRH), besides stimulating GH secretion in the ant...

ea0081p436 | Pituitary and Neuroendocrinology | ECE2022

Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-β-induced toxicity

Pedrolli Francesca , Banfi Dana , Gesmundo Iacopo , Guglielmotto Michela , Tamagno Elena , Schally Andrew V. , Ghigo Ezio , Granata Riccarda

Neurogenesis, the process by which new neurons are generated from precursors, persists in discrete regions of the adult hippocampus. The hippocampus is critical for learning and memory and is the main target of Alzheimer’s Disease (AD), which causes massive neuronal death, reduction in neurogenesis, and impairment in cognitive functions. Therefore, preventing neuronal loss or increasing the production of new neurons may represent a potential therapeutic strategy to reduce...

ea0063p266 | Pituitary and Neuroendocrinology 1 | ECE2019

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH and GH-secreting pituitary adenoma cell lines

Fanciulli Alessandro , Gesmundo Iacopo , Gamba Giacomo , Castano Justo P , Luque Raul M , Alvarez Clara V , Dieguez Carlos , Chiara Zatelli Maria , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are p...

ea0070yi11 | Young Investigators | ECE2020

Growth hormone-releasing hormone (GHRH) antagonists increase the sensitivity to radiotherapy in lung cancer cells

Gesmundo Iacopo , Dematteis Alessandro , Fanciulli Alessandro , Romana Giglioli Francesca , Cai Renzhi , Sha Wei , Ricardi Umberto , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Growth hormone-releasing hormone (GHRH), apart from stimulating GH secretion in the pituitary, exerts many extrapituitary functions, including stimulation of cell proliferation and survival. GHRH and its receptor splice variants (SVs) are expressed in different cancer cell types, where they modulate cell growth. It has been shown that GHRH antagonists exert anticancer activities in a variety of tumors, including malignant pleural mesothelioma and lung cancer, one of the leadin...